FDA orphan designation for zenocutuzumab‑zbco targets NRG1 fusion–positive advanced cholangiocarcinoma, a small molecular subset within an aggressive malignancy with <15% five-year survival. Orphan ...

Zenocutuzumab--zbco, marketed as BIZENGRI (R), received Breakthrough Therapy Designation from the FDA in October 2025 and was granted accelerated approval in December 2024 for adults with advanced ...

Jammu and Kashmir faces significant infrastructure deficits in sectors such as road connectivity, water supply, sewerage, tourism and power, Chief Minister ...

Ahead of teasing the first exhibitors for this year’s FOS Future Lab presented by Randox, we’ve taken a look at MIT ...